Leukotriene receptor antagonists - Risks and benefits for use in paediatric asthma

Expert Opinion on Drug Safety

Volumn 3, Issue 3, 2004, Pages 173-185

  Spahr, Jonathan E ^a   Krawiec, Marzena ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Corticosteroids; Inflammation; Leukotrienes(LTs); Paediatric asthma

Indexed keywords

ACETYLSALICYLIC ACID; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID DERIVATIVE; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE PLUS SALMETEROL; GLUCOCORTICOID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PEPTIDOLEUKOTRIENE; PLACEBO; PRANLUKAST; PREDNISONE; SALMETEROL; THEOPHYLLINE; WARFARIN; ZAFIRLUKAST; ZILEUTON;

ADOLESCENT; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHOSPASM; CHEWABLE TABLET; CHILD; CHILDHOOD DISEASE; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG GRANULE; DRUG INDICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EXERCISE INDUCED ASTHMA; HUMAN; INFLAMMATION; LIVER DYSFUNCTION; MAINTENANCE THERAPY; MUCUS SECRETION; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS; SUSPENSION; SYRUP;

EID: 2942689443     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.3.173     Document Type: Review

References (101)

1. CIBA GEIGY SYMPOSIUM: Terminology, definitions, and classifications of chronic pulmonary emphysema and related conditions. Thorax (1959) 14:286-299.
2. UNGER L: The pathology of bronchial asthma. Arch. Intern. Med. (1922) 30:689-760.
3. BURANAKUL B, WASHINGTON J, HILMAN B et al.: Causes of death during acute asthma in children. Am. J. Dis. Child. (1974) 128(3):343-350.
4. BARNES PJ: Frontiers in medicine: new aspects of asthma. J. Intern. Med. (1992) 231:453-461.
5. MURPHY RC, HAMMARSTROM S, SAMUELSSON B: Leukotriene C, a slow reacting substance (SRS) from mouse mastocytoma cells. Proc. Natl. Acad. Sci. USA (1979) 76:4275-4279.
6. DRAZEN JM, AUSTEN KF, LEWIS RA et al.: Comparative airway and vascular activities of leukotrienes C and D in vivo and in vitro. Proc. Natl. Acad. Sci. USA (1980) 77(7):4354-4358.
7. DAHLEN SE, HEDQVIST P, HAMMARSTROM S et al.: Leukotrienes are potent constrictors of human bronchi. Nature (1980) 288(5790):484-486.
8. GRIFFIN M, WEISS JW, LEITCH AG et al.: Effects of leukotriene D on the airways in asthma. N. Engl. J. Med. (1983) 308(8):436-439.
9. 4 in humans. Am. Rev. Respir. Dis. (1985) 131(3):368-372.
10. WEISS JW. DRAZEN JM, COLES N et al.: Bronchoconstrictor effects of leukotriene C in humans. Science (1982) 216(4542):196-198.
11. SHIMIZU T, HIRANO H, MAJIMA Y et al.: A mechanism of antigen-induced mucus production in nasal epithelium of sensitized rats. A comparison with lipopolysaccharide-induced mucus production. Am. J. Respir. Crit. Care Med. (2000) 161(5):1648-1654.
12. (4) and granulocytic infiltration into asthmatic airways. Lancet (1993) 341:989-990.
13. MUNOZ NM, LEFF AR: Blockade of eosinophil migration by 5-lipoxygenase and cyclooxygenase inhibition in explanted guinea pig trachealis. Am. J. Physiol. (1995) 269:446-454.
14. KELLAWAY CH, TRETHEWIE EW: Liberation of slow-reacting smooth muscle stimulating substance of anaphylaxis. J. Exp. Physiol. (1940) 30:121-148.
15. BROCKLEHURST WE: The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J. Physiol. (1960) 151:416-435.
16. HOLGATE ST, BRADDING P, SAMPSON AP: Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J. Allergy Clin. Immunol. (1996) 98:10-13.
17. LYNCH KR, O'NEILL GP, LIU Q et al.: Characterization of the human cysteinyl leukotriene cysLT1 receptor. Nature (1999) 399(6738):789-793.
18. HEISE CE, O'DOWD BF, FIGUEROA DJ et al.: Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. (2000) 275(39):30531-30516.
19. 4 and to methacholine in patients with asthma and normal controls. N. Engl. J. Med. (1986) 315:480-484.
20. 4 and histamine in normal human subjects. Thorax (1984) 39:500-504.
21. PANETTIERI RA, TAN EM, CIOCCA V et al.: Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am. J. Respir. Cell Mol. Biol. (1998) 19(3):453-461.
22. LEWIS RA, AUSTEN KF, SOBERMAN RJ: Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. (1990) 323:645-655.
23. CHUNG KF: Leukotriene receptor antagonists and biosynthesis inhibitors: potential breakthrough in asthma therapy. Eur. Respir. J. (1995) 8:1203-1213.
24. 4, increase the release of mucus from human airways in vitro. Am. Rev. Respir. Dis. (1982) 126:449-451.
25. SHELHAMER JH, MAROM Z, SUN F et al.: The effects of arachinoids and leukotrienes on the release of mucus from human airways. Chest (1982) 81:36-37.
26. 4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects. Am. J. Respir. Crit. Care Med. (1999) 159:1562-1567.
27. 4 in subjects with mild asthma. Am. J. Respir. Crit. Care Med. (1997) 155:1247-1253.
28. 4-induced bronchoconstriction in subjects with asthma: a concentration - effect study of ICI 204,219. Clin. Pharmacol. Ther. (1993) 54:430-436.
29. 4 receptor antagonism in the airways of patients with asthma. Clin. Pharmacol. Ther. (1997) 61:83-92.
30. 4) challenge in normal volunteers. Thorax (1997) 52:519-522.
31. CALHOUN WJ, LAVINS BJ, MINKWITZ MC et al.: Effect of zafirlukast (Accolate) on cellular mediators of inflammation. Bronchoalveolar lavage fluid findings after segmental antigen challenge. Am. J. Respir. Crit. Care Med. (1998) 157:1381-138.
32. NAKAMURA Y, HOSHINO M, SIM JJ et al.: Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax (1998) 53:835-841.
33. KNORR B, MATZ J, BERNSTEIN JA et al.: Montelukast for chronic asthma in 6- to 14-year old children: a randomized, double-blind trial. JAMA (1998) 279:1181-1186.
34. REISS TF, CHERVINSKY P, DOCKHORN RJ et al.: Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch. Intern. Med. (1998) 158:1213-1220.
35. O'BYRNE PM, DOLOVICH J, HARGREAVE FE: Late asthmatic responses. Am. Rev. Respir. Dis. (1987) 136:740-751.
36. DIAMANT Z, GROOTENDORST DC, VESELIC-CHARVAT M et al.: The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin. Exp. Allergy (1999) 29(1):42-51.
37. MACFARLANE AJ, DWORSKI R, SHELLER JR et al.: Sputum cysteinyl leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am. J. Respir. Crit. Care Med. (2000) 161(5):1553-1558.
38. O'SULLIVAN S, ROQUET A, DAHLEN B et al.: Urinary excretion of inflammatory mediators during allergen-induced early and late phase asthmatic reactions. Clin. Exp. Allergy (1998) 28:1332-1339.
39. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis. (1990) 142:112-119.
40. 4 levels during early and late asthmatic responses. J. Allergy Clin. Immunol. (1990) 86:211-220.
41. SMITH HR, LARSEN GL, CHERNIAK RM et al.: Inflammatory cells and eicosanoid mediators in subjects with late asthmatic responses and increases in airway responsiveness. J. Allergy Clin. Immunol. (1992) 89:1076-1084.
42. HAMILTON A, FAIFERMAN I, STOBER P et al.: Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early and late phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J. Allergy Clin. Immunol. (1998) 102:177-183.
43. RASMUSSEN JB, ERIKSSON LO, MARGOLSKEE DJ et al.: Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J. Allergy Clin. Immunol. (1992) 90:193-201.
44. TAYLOR IK, O'SHAUGHNESSY KM, FULLER RW et al.: Effect of cysteinyl-leukotriene receptor antagonists ICI 204,219, on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet (1991) 337:690-694.
45. FINDLAY SR, BARDEN JM, EASLEY CB et al.: Effect of the oral leukotriene antagonist, ICI 204,219 on antigen-induced bronchoconstriction in subjects with asthma. J. Allergy Clin. Immunol. (1992) 89:1040-1045.
46. TANIGUCHI Y, TAMURA G, HONMA M et al.: The effect of an oral leukotriene antagonist, ONO-1078, on allergen-induced immediate bronchoconstriction in asthmatic subjects. J. Allergy Clin. Immunol. (1993) 92:507-512.
47. LEIGH R, VETHANAYAGAM D, YOSHIDA M et al.: Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am. J. Respir. Crit. Care Med. (2002) 166(9):1212-1217.
48. 4 levels after allergen and exercise challenge in bronchial asthma. Am. Rev. Respir. Dis. (1991) 144:1411-1415.
49. 4-receptor antagonist. N. Engl. J. Med. (1990) 323:1736-1739.
50. 4 receptor antagonist. Am. Rev. Respir. Dis. (1992) 145:746-749.
51. 4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J. Pediatr. (1999) 134:273-279.
52. KEMP JP, DOCKHORN RJ, SHAPIRO GG et al.: Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J. Pediatr. (1998) 133(3):424-428.
53. LEFF JA, BUSSE WW, PEARLMAN D et al.: Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med. (1998) 339:147-152.
54. HOFSTRA WB, STERK PJ, NEIJENS HJ et al.: Short-term treatment with zafirlukast, sodium cromoglycate or placebo in reducing exercise induced bronchoconstriciton in adolescent asthmatics. Eur. Respir. J. (1997) 10(Suppl.):220. Abstract.
55. EDELMAN JM, TURPIN JA, BRONSKY EA et al.: Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann. Intern. Med. (2000) 132(2):97-104.
56. MCFADDEN ER, GILBERT IA: Exercise-induced asthma. N. Engl. J. Med. (1994) 330:1362-1367.
57. SIMONS FE, GERSTNER TV, CHEANG MS: Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics (1997) 99(5):655-659.
58. RAMAGE L, LIPWORTH BJ, INGRAM CG et al.: Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir. Med. (1994) 88:363-368.
59. BOULET LP, BECKER A, BERUBE D et al.: Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group. Can. Med. Assoc. J. (1999) 161 (11Suppl.):S1-S61.
60. NIH/NHLBI: Guidelines for the diagnosis and management of asthma. US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. Bethesda, MD, USA (2002).
61. GINA: Global Strategy for Asthma Management & Prevention Workshop Report, National Institutes of Health.
62. 4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am. J. Respir. Crit. Care Med. (1994) 150(3):618-623.
63. SUISSA S, DENNIS R, GREENBERGER PA et al.: Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med. (1997) 126:177-183.
64. KNORR B, FRANCHI LM, BISGAARD H et al.: Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics (2001) 108(3):E48.
65. PEARLMAN DS, LAMPL KL, DOWLING PJ, MILLER CJ, BONUCCELLI CM: Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Clin. Ther. (2000) 22:732-747.
66. MALMSTROM K, RODRIGUEZ-GOMEZ G, GUERRA J et al.: Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/beclomethasone study group. Ann. Intern. Med. (1999) 130(6):487-495.
67. DRAZEN JM, YANDAVA CN, DUBE L et al.: Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat. Genet. (1999) 22:168.
68. WECHSLER ME, ISRAEL E: Pharmacogenetics of treatment with leukotriene modifiers. Curr. Opin. Allergy Clin. Immunol. (2002) 2:395-401.
69. CYLLY A, KARA A, OZDEMIR T et al.: Effects of oral montelukast on airway function in acute asthma. Respir. Med. (2003) 97:533-536.
70. CAMARGO CA, SMITHLINE HA, MALICE MP et al.: A randomized, controlled trial of intravenous montelukast in acute asthma. Am. J. Respir. Crit. Care Med. (2003) 167:528-533.
71. DICPINIGAITIS PV, DOBKIN JB, REICHEL J: Antitussive effect of the leukotriene receptor antagonist zafirlukast in subjects with cough-variant asthma. J. Asthma (2002) 39:291-297.
72. KRAWIEC ME, WESTCOTT JY, CHU HW et al.: Persistent wheezing in very young children is associated with lower respiratory inflammation. Am. J. Respir. Crit. Care Med. (2001) 163:1338-1343.
73. CROCKER IC, ZHOU CY, BEWTRA AK et al.: Glucocorticosteroids inhibit leukotriene production. Ann. Allergy Asthma Immunol. (1997) 78:497-505.
74. VAN SCHAIK SM, TRISTAM DA, NAGPAL IS et al.: Increased production of IFN-γ and cysteinyl leukotrienes in virus-induced wheezing. J. Allergy Clin. Immunol. (1999) 103(4):630-636.
75. VOLOVITZ B, WELLIVER RC, DE CASTRO G et al.: The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr. Res. (1988) 24:504-507.
76. 4 in respiratory tract during acute vital infection. J. Pediatr. (1988) 112:218-222.
77. BISGAARD H: A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am. J. Respir. Crit. Care Med. (2003) 167:379-383.
78. LOFDAHL CG, REISS TF, LEFF JA et al.: Randomized, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. Br. Med. J. (1999) 319:87-90.
79. TAMAOKI J, KONDO M, SAKAI N et al.: Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am. J. Respir. Crit. Care Med. (1997) 155:1235-1240.
80. TOHDA Y, FUJIMURA M, TANIGUCHI H et al.: Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin. Exp. Allergy (2002) 32:1180-1186.
81. LAVIOLETTE M, MALMSTROM K, LU S et al.: Montelukast added to inhaled beclomethasone in treatment of asthma. Am.J. Respir. Crit. Care Med. (1999) 160(6):1862-1868.
82. VIRCHOW JC, PRASSE A, NAYA I et al.: Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am. J. Respir. Crit. Care Med. (2000) 162(2):578-585.
83. BUSSE WW, NELSON H, WOLFE J et al.: Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. J. Allergy Clin. Immunol. (1999) 103:1075-1080.
84. NELSON HS, BUSSE WW, KERWIN E et al.: Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J. Allergy Clin. Immunol. (2000) 106(6):1088-1095.
85. SIMONS FE, VILLA JR, LEE BW et al.: Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J. Pediatr. (2001) 138(5):694-698.
86. PHIPATANAKUL W, GREENE C, DOWNES SJ et al.: Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann. Allergy Asthma Immunol. (2003) 91(1):49-54.
87. VOLOVITZ B, TABACHNIK E, NUSSINOVITCZ M et al.: Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in respiratory tract of children with persistent asthma. J. Allergy Clin. Immunol. (1999) 104:1162-1167.
88. MASPERO JF, DUENAS-MEZA E, VOLOVITZ B et al.: Oral montelukast versus beclomethasone in 6 - 11 year old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction and adherence with therapy. Curr. Med. Res. Opin. (2001) 17:96-104.
89. NATHAN RA, MINKWITZ MC, BONUCCELLI CM: Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. Ann. Allergy Asthma Immunol. (1999) 82:497-503.
90. DUCHARME FM: Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br. Med. J. (2003) 326:621.
91. BUKSTEIN DA, LUSKIN AT, BERNSTEIN A: 'Real-world' effectiveness of daily controller medicine in children with mild persistent asthma. Ann. Allergy Asthma Immunol. (2003) 90(5):543-549.
92. ARMSTRONG EP, MALONE DC: Fluticasone is associated with lower asthma-related costs than leukotriene modifiers in a real world analysis. Pharmacotherapy (2002) 22:1117-1123.
93. KATIAL RK, STELZLE RC, BONNER MW, MARINO M, CANTILENA LR, SMITH LJ: A drug-interaction between zafirlukast and theophylline. Arch. Intern. Med. (1998) 158:1713-1715.
94. GREEN RL, VAYONIS AG: Churg-Strauss syndrome after zafirlukast in two patients not receiving steroid treatment. Lancet (1999) 353:725-726.
95. KINOSHITA M, SHIRAISHI T, KOGA T et al.: Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast. J. Allergy Clin. Immunol. (1999) 103(3 Pt 1):534-535.
96. WECHSLER ME, GARPESTAD E, FLIER SR et al.: Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA (1998) 279(6):455-457.
97. WECHSLER ME, FINN D, GUNAWARDENA D et al.: Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest (2000) 117:708-713.
98. MARTIN RM, WILTON LV, MANN RD: Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated condition: retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiol. Drug Saf. (1999) 8:179.
99. TUGGEY JM, HOSKER HS: Churg-Strauss syndrome associated with montelukast therapy. Thorax (2000) 55:805-806.
100. JAMALEDDINE G, DIAB K, TABBARAH Z et al.: Leukotriene antagonists and the Churg-Strauss syndrome. Semin. Arthritis Rheum. (2002) 31:218-227.
101. SCHURMAN SJ, ALDERMAN JM, MASSANARI M et al.: Tubulointerstitial nephritis induced by the leukotriene receptor antagonist pranlukast. Chest (1998) 114:1220-1223.